{"id":"W4250326583","doi":"10.31525/cmr-1d27113","title":"Simultaneous review decisions for pembrolizumab plus lenvatinib in Australia, Canada and US","year":2019,"lang":"en","type":"article","venue":"Case Medical Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Lenvatinib; Pembrolizumab; Medicine; Internal medicine; Immunotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004079796,0.0001347862,0.0003528144,0.002342434,0.003259765,0.003196476,0.001051649,0.002732479,0.005134747],"category_scores_gemma":[0.02993647,0.0003301502,0.0006418102,0.001668838,0.0009112921,0.0009151777,0.0009903413,0.001943163,0.0003014659],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.02974399,"about_ca_system_score_gemma":0.07392748,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.671142,"about_ca_topic_score_gemma":0.8897527,"domain_scores_codex":[0.9943748,0.0007719624,0.0006973853,0.0005331625,0.002148889,0.001473903],"domain_scores_gemma":[0.9761229,0.005341438,0.002434043,0.0003592957,0.009172251,0.006570017],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"observational","study_design_scores_codex":[0.00179134,0.0002536112,0.2208993,0.001658813,0.0008557353,0.02397389,0.006024345,0.001983967,0.00496823,0.03577426,0.4833557,0.2184608],"study_design_scores_gemma":[0.0003323878,0.0002309486,0.3016281,0.002828295,0.001153236,0.01197771,0.009699585,0.00275435,0.002268279,0.006555139,0.660306,0.0002658684],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.3624851,0.04141904,0.0008619917,0.385836,0.004206527,0.0007335854,0.003057668,0.00008816538,0.201312],"genre_scores_gemma":[0.8753668,0.01527216,0.002952184,0.07347059,0.001946771,0.0001812806,0.0009610387,0.00007549162,0.02977363],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.328858,"threshold_uncertainty_score":0.6615894,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1135547015898747,"score_gpt":0.4522904327273504,"score_spread":0.3387357311374757,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}